aminoimidazole carboxamide has been researched along with Macular Degeneration in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Homma, K; Kawashima, H; Nagai, N; Narimatsu, T; Osada, H; Ozawa, Y; Toda, E; Tsubota, K | 1 |
| Barbisan, PRT; Efstathiou, NE; Georgakopoulos, CD; Konstantinou, EK; Maidana, DE; Miller, JW; Moustafa, GA; Notomi, S; Vavvas, DG | 1 |
| Chung, EJ; Efstathiou, NE; Konstantinou, EK; Maidana, DE; Miller, JW; Vavvas, DG; Young, LH | 1 |
3 other study(ies) available for aminoimidazole carboxamide and Macular Degeneration
| Article | Year |
|---|---|
Neuroprotective and vision-protective effect of preserving ATP levels by AMPK activator.
Topics: Adenosine Triphosphate; Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Cell Line; Electron Transport Complex IV; Macular Degeneration; Male; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxygen Consumption; Protein Kinases; Retina; Ribonucleotides; Ultraviolet Rays | 2020 |
Acadesine suppresses TNF-α induced complement component 3 (C3), in retinal pigment epithelial (RPE) cells.
Topics: Adenosine; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Cell Line; Cells, Cultured; Complement Activation; Complement C3; Humans; Macular Degeneration; Phosphorylation; Retinal Pigment Epithelium; Retinal Pigments; Ribonucleosides; Ribonucleotides; Tumor Necrosis Factor-alpha | 2020 |
AICAR suppresses TNF-α-induced complement factor B in RPE cells.
Topics: Aminoimidazole Carboxamide; Cell Line; Clustered Regularly Interspaced Short Palindromic Repeats; Complement Activation; Complement Factor B; Dipyridamole; Humans; Macular Degeneration; Phosphotransferases (Phosphate Group Acceptor); Retinal Pigment Epithelium; Ribonucleosides; Tubercidin; Tumor Necrosis Factor-alpha | 2017 |